An initial UTI vaccine candidate comprised of FimH in complex with periplasmic chaperone FimC showed signs of efficacy in cynomolgus macaques and was subsequently evaluated in a small Phase 1 clinical study with the TLR4 ligand monophosphoryl lipid A (MPL) adjuvant (22, 28). The gene discussed is TLR4; the disease is bacterial urinary tract infection.